The gsa2 mutant was selected because its seedlings show fainter green leaves than gsa1 ( When the soluble recombinant GSAAT At variants were electrophoretically separated on a non-reducing PA gel, GSAAT(WT) was found to contain almost equal amounts of the monomer and dimer forms ( Figure 6A ), while GSAAT(C168S) and GSAAT(C190S) expressed only small amounts of the dimer, and GSAAT(C396S) did not migrate as a dimer ( Figure 6A )
Kern JK, Jones AM
Route Design & Feasibility Capabilities include: Review of the target structure, desired attachment site, and whether the project is aiming for an S-conjugate, terminally modified glutathione derivative, or protected synthetic intermediate Selection of direct conjugation, protected-thiol strategy, amide coupling, thiol-reactive labeling, or orthogonal handle installation based on substrate chemistry Assessment of likely competing reactions such as hydrolysis, oxidation, disulfide formation, or multi-site functionalization Early planning for purification mode, storage form, and the analytical evidence needed for project success Typical applications: Metabolite standard planning, reactive metabolite follow-up, feasibility assessment for custom GSH reagents, and route selection for difficult customer-defined substrates Small-Molecule GSH Adducts Capabilities include: Synthesis of glutathione adducts from electrophilic substrates such as epoxides, quinones, activated alkenes, halo-containing intermediates, and other reactive small molecules when chemically appropriate Development of routes that balance conversion, selectivity, and substrate stability instead of maximizing reaction severity Support for customer-supplied compounds, literature-reported adduct targets, or hypothesized structures arising from metabolism studies Isolation of metabolite-like conjugates for structural confirmation, comparison standards, or mechanistic research Typical applications: LC-MS reference standards, GST substrate studies, covalent drug follow-up, electrophile reactivity studies, and mercapturate-pathway research support Labeled GSH Derivatives Capabilities include: Installation of biotin, fluorophore, PEG-like spacer, affinity, or azide/alkyne handles on glutathione using a route matched to the desired preserved functionality Control over whether the cysteine thiol remains free, is temporarily protected, or is intentionally used as the point of attachment Design of glutathione-linked reagents for capture studies, probe development, and assay-format optimization Coordination with thiol-reactive chemistries when maleimide-style or related handle selection is part of the design logic Focus areas: Functional handle placement, label compatibility, manageable polarity, and conjugate architectures that are easier to purify and verify Purification & Structure QC Capabilities include: Purification planning for highly polar conjugates using fit-for-purpose chromatographic methods Identity and composition assessment by LC-MS, HRMS, and NMR as appropriate for the target structure Monitoring of free glutathione, oxidized glutathione, regioisomeric impurities, and residual label or linker-related byproducts Delivery of structured analytical summaries to support method transfer, repeat synthesis, and downstream study design Deliverables: Purified conjugate, analytical data package, handling recommendations, and project-specific notes on stability and interpretation limits where relevant Key Design Parameters for Glutathione Conjugation Projects Successful glutathione conjugation depends on how the reactivity of glutathione is matched to the substrate, the intended point of attachment, and the downstream use of the final conjugate
10.1007/s12035-018-1398-9 165 TanS
Currently there appears to be a group of genes that would influence variability in response and toxicity in cisplatin-based therapies which we present here in this up-dated review
